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Dr David A. Fullerton (Aurora, Colo). Dr Lee, I enjoyed your
presentation very much, and I think it is important that we in the
audience acknowledge that it is not necessarily easy to (a) collate
the information, the data on such a cohort of patients, and then (b)
try to drill down and actually make sense of it, so I think you and
your group are to be congratulated on that.
Having said that, I think it is very important, as you have done,
to acknowledge the limitations of such studies. It is a very hetero-
geneous group of patients. You appropriately acknowledge the
many recognized and unrecognized confounding variables that
may have influenced the data. Having said that, just as you accu-
rately pointed out, the prevailing literature strongly supports the
notion that there seems to be an association with statin usage
around the time of a variety of different types of cardiac operations
and favorable outcomes. That said, I wanted to invite you to spec-
ulate a little bit on how the mechanism of such an association
might be explored. For instance, I think it would be a pretty
straightforward matter to take blood or tissue samples seeking
evidence of proinflammatory stimulation or anti-inflammatory
effects of statins, that sort of thing. I was curious—have you and
your group discussed this? Have you embarked on this, or would
that be of interest to you?
Again, I enjoyed your talk very much and thank you.
Dr Lee. Thank you for those comments and the questions.
I agree. We have one of a few different ways that we are sorting
out where we go to next. Clearly we need to do this in a more
prospective fashion and we need to look a little bit better at the
patients who were not started preoperatively for 6 months but
were started postoperatively and what happens to them long-
term as well. So there are still some things within the data set
that we need to capture more effectively; however, in the next
step, we do need to look at troponins, CK MBs, and CRPs around
the time of surgery in the users versus nonusers, and do a much
more sophisticated analysis of that patient population. I think
what really needs to be done is a much bigger prospective study
on a wider scale. Again, and I appreciate your comments—this
is the beginning and it may or may not be real but I know I am tak-
ing an aspirin a day and that was based on an early study a long
time ago. Wemay evolve to the point where we start taking a statin
a day, too.
Dr Irving Kron (Charlottesville, Va). Dr Lee, I enjoyed your
talk. We have published similar data just a couple of years ago
and, in fact, we had proposed—as you all know, there is a network
at the NHLBI doing cardiovascular surgical research and this is
one study we proposed in valvular heart disease. I think it is
a real thing and there are data at least in animals, Dr. Fullerton,
that looks at these issues, so you have convincing data. Are you
going to have every valve patient that comes in started on a statin?
Dr Lee. We already do. The question is how to get them
6 months before. I think we need to do again is if this gets a little
more weight we need to not only present it at a forum like this. We
had an offshoot of this presentation that we presented at the ACC
but we need to help our cardiology colleagues look at this issue as
well.
Dr John C. Chen (Honolulu, Hawaii). As an extension of that,
how long in advance would you have them start on the statin prior
to surgery?gery c November 2010
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what the trial would be for and as surgeons—I don’t know about
your practice but a lot of my practice is in-house, so I think at
time of diagnosis but if you really want to look at it, you look at
your valve practice. Take the valve people. You could probably
hold off at least 2 to 4 weeks on the valve and design it that way.
Otherwise, it actually probably is not very good because if you
have to wait too long for the valve population this kind of stuff
is not good. This won’t help them at all unless even that 2-month
window makes a difference and that is why we need to start with
a trial.
Dr Craig Baker (Los Angeles, Calif). Thank you for an excel-
lent presentation. As we heard a couple days ago, there is very
convincing evidence that children with congenital heart disease
are becoming a large growing population and we are increasingly
operating on teenagers and young adults with tetrology repairs,
putting in, as we heard, bioprosthetic valves. This may require a lit-
tle bit of speculation but what would be your advice in this young
population who are having new valves put in as many of them areThe Journal of Thoracic and Car
Delective and we would have time to start preoperative therapy. It is
not usually in an urgent setting. In fact, I was rounding last week
and one of our 25-year-olds who we did this procedure in and the
team had started them on statin therapy and we at rounds said, hey,
we don’t want to put this young patient on medication he may take
for the next 30 to 40 years. Could you offer any advice for this
particular patient population?
Dr Lee. As you know, the recommendation from the ACCHA
was to start it even in the teen population, which was a little contro-
versial, but we also have done an analysis of purely valve patients
looking at users, nonusers, stoppers, and starters. In fact, we found
a survival advantage for those patients who were put on statin
therapy and continued on it even when it was postoperative.
When patients stopped it for any reason whatsoever they had a sur-
vival disadvantage. Again, that’s cloudy. Who knows why they
stopped it? But at least it is our preliminary impression that, yes,
patients undergoing valve surgery, particularly with bioprosthetic
valves, should be getting statins. We need more literature to really
support that but that would be our practice in the current era.diovascular Surgery c Volume 140, Number 5 1027
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